TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02392234
Drug: Placebo matched to Ivacaftor
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet, oral use
Study: NCT04071106
Drug: Turmeric Extract
Normalized name: Turmeric Extract
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
Study: NCT04071106
Drug: Turmeric Extract in Olive oil
Normalized name: Turmeric oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
Study: NCT04071106
Drug: Petrolatum
Normalized name: Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
Study: NCT04071106
Drug: calcipotriol/ Betamethasone
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
Study: NCT02313675
Drug: Ketorolac Tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02313675
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00281892
Drug: Fludarabine mono
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles with no additional growth factor support.~Group 2 - Patients with an initial Hb-value more than 12 g/dl start to receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles . Patients of group 2 will be eventually randomized at later timepoints, if the Hb-value drops below 12 g/dl. Randomized patients will receive either 500 mcg darbepoetin alfa subcutaneously every 3 weeks or continue therapy with fludarabine without additional administration of darbepoetin alfa.
Study: NCT02260024
Drug: Pramipexole IR tablets
Normalized name: pramipexole Oral Tablet
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02260024
Drug: Pramipexole SR C
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02260024
Drug: Pramipexole SR C2
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02260024
Drug: Pramipexole SR C2A
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02260024
Drug: Pramipexole SR C2B
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01181154
Drug: rituximab (Mabthera®)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1000 mg at day 1 and day 15
Study: NCT01634789
Drug: bazedoxifene
Normalized name: Bazedoxifene
DrugBank: Bazedoxifene (DB06401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg oral tablet, single dose
Study: NCT01634789
Drug: bazedoxifene/conjugated estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg / 0.625 mg oral tablet, single dose
Study: NCT02052440
Drug: Baclofen
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment arm: baclofen 10mg tid
Study: NCT03427866
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib is a medication that blocks certain proteins called tyrosine kinases. Specifically, it blocks tyrosine kinases called JAK2. The JAK2 pathway is over active in the disease, acute myeloid leukemia.
Study: NCT00697060
Drug: Imexon + docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imexon at 1300 mg/m2 days 1-5 Docetaxel at 75 mg/m2 day 1
Study: NCT01206972
Drug: Rivaroxaban (BAY59-7939)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: daily dose: 5mg/day (5mg, once daily) for 11 to 12 days (±2 days)
Study: NCT01206972
Drug: Rivaroxaban (BAY59-7939)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: daily dose: 7.5mg/day (7.5mg, once daily) for 11 to 12 days (±2 days)
Study: NCT01206972
Drug: Rivaroxaban (BAY59-7939)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: daily dose: 10mg/day (10mg, once daily) for 11 to 12 days (±2 days)
Study: NCT01206972
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily dose: 40mg/day (20mg, twice daily) for 10 to 11 days (±2 days)
Study: NCT00306475
Drug: divalproex sodium ER
Normalized name: Divalproex Sodium ER
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: divalproex sodium ER1000 mg
Study: NCT02848105
Drug: VPA
Normalized name: VPA
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid with 1000mg loading dose with 500mg q12 4 hours later to maintain a trough level above 75ug/ml
Study: NCT00090519
Drug: ruboxistaurin
Normalized name: RUBOXISTAURIN
DrugBank: Ruboxistaurin (DB11829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 mg once daily (QD) oral for up to 36 months
Study: NCT00370942
Drug: GW823093C C
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: C=25 mg
Study: NCT03563690
Drug: Celebrex
Normalized name: Celebrex
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Celebrex (Celebrex, Capsules, Pfizer Pharmaceuticals Ltd), which will be applied 1 time daily( taken 0.2g one time orally ) Time of treatment :4 weeks Other Name: celecoxib
Study: NCT01183767
Drug: Epigallocatechin-Gallate
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG in a dosage of up to 10mg/kg body weight
Study: NCT02378649
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil administration in the cardiac ICU following Mitral Valve Surgery concomitant with best practice usual care
Study: NCT00171769
Drug: Certoparin
Normalized name: certoparin
DrugBank: Certoparin (DB09261)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03539952
Drug: Penicillamine (D1-W12)
Normalized name: Penicillamine
DrugBank: Penicillamine (DB00859)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillamine during baseline period (D1-W12)
Study: NCT03539952
Drug: TETA 4HCL (W12-60)
Normalized name: TETA
DrugBank: Triethylenetetramine (DB06824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TETA 4HCL during post randomisation and 1st extension period (W12-W60)
Study: NCT03539952
Drug: Penicillamine (W12-W60)
Normalized name: Penicillamine
DrugBank: Penicillamine (DB00859)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillamine during rondomisation and 1st extension period period (W12-W60)
Study: NCT03539952
Drug: TETA 4HCL (60-<W108)
Normalized name: TETA
DrugBank: Triethylenetetramine (DB06824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TETA 4HCL during 2nd extension period (W60-\<W108)
Study: NCT02424201
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: experimental
Study: NCT02424201
Drug: vitamin c
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: control
Study: NCT04094519
Drug: enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral
Study: NCT04094519
Drug: enzalutamide Placebo
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral
Study: NCT04094519
Drug: digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT03965949
Drug: Hormone Replacement cycle 1
Normalized name: adrenocorticotropic hormone 1-24
DrugBank: Tetracosactide (DB01284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement cycle (cyclacur) without GnRHa suppression with luteal support (progesterone)
Study: NCT03965949
Drug: Hormone Replacement cycle 2
Normalized name: Growth hormone-releasing peptide 2
DrugBank: Pralmorelin (DB18252)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Hormone Replacement cycle with GnRHa suppression
Study: NCT03301870
Drug: Positive Control
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Lauryl Sulfate 0.05% (w/v), USP in sterile, distilled Water for Injection, USP
Study: NCT03301870
Drug: Negative Control
Normalized name: GLYCERIN NEGATIVE CONTROL
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water for Injection, USP
Study: NCT00715351
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Physician decides which insulin should be prescribed, selection of subjects will be at the discretion of participating physician
Study: NCT03115099
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered subcutaneously
Study: NCT03115099
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered orally
Study: NCT00259142
Drug: Chloroquine, sulphadoxine-pyrimethamine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02261805
Drug: Ganetespib
Normalized name: Ganetespib
DrugBank: Ganetespib (DB12047)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01887275
Drug: conventional interferon-α
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the conventional interferon-α treatment group received subcutaneouslly injection of 5 million units of conventional interferon-α in three times per week for at least 24 weeks.
Study: NCT02593760
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib will be administered PO BID at a starting dose depending on the participants's baseline platelet count for up to 48 weeks.
Study: NCT02593760
Drug: Vismodegib
Normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Vismodegib will be administered at a dose of 150 mg PO QD for up to 48 weeks.
Study: NCT03983759
Drug: sintilimab maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: the patients with CR, PR or SD after the chemotherapy plus R-CIK will receive sintilimab maintenance therapy. The dose of sintilimab is fixed at 200mg every three weeks.
Study: NCT01319838
Drug: Isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: \>12 kg: 160 mg/m2/day, given PO, divided BID \<=12 kg: 5.33 mg/kg/day, given PO, dividied BID doses given days 1-14 of 28 day cycle for 24 consecutive cycles
Study: NCT00345046
Drug: Pred Forte
Normalized name: Pred Forte
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Four drops daily decreasing to once daily over four weeks.
Study: NCT04718259
Drug: intrathecal bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The use of intrathecal bupivacaine will be compared to the use of intrathecal bupivacaine and midazolam.
Study: NCT04718259
Drug: midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: midazolam
Study: NCT02103166
Drug: Hyoscine bromide
Normalized name: N-methylhyoscine bromide
DrugBank: Methscopolamine bromide (DB00462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of hyosine bromide diluted in 100 ml of physiological serum (0.9% NaCl).
Study: NCT02103166
Drug: Physiological serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of physiological serum (0.9% NaCl).
Study: NCT00980213
Drug: sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: sunitinib 50 mg, per os, daily for 4 weeks then 2 weeks pause, duration months
Study: NCT02897206
Drug: Imipenem
Normalized name: Imipenem
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A wide-spectre antibiotic from the carbapenem group
Study: NCT00914641
Drug: Apixaban IR
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: immediate release tablet, 10 mg, single dose
Study: NCT00914641
Drug: Apixaban MR1
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: modified release tablet 1, 10 mg, single dose
Study: NCT00914641
Drug: Apixaban MR2
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: modified release tablet 2, 10 mg, single dose
Study: NCT00914641
Drug: Apixaban MR3
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: modified release tablet 3, 10 mg, single dose
Study: NCT01281657
Drug: fingolimod
Normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04535856
Drug: allogeneic mesenchymal stem cell
Normalized name: allogeneic mesenchymal stem cells derived neuronal regeneration promoting cells
DrugBank: CLZ-2002 (DB18638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assignment of Administration Group allogeneic mesenchymal stem cell:~* Low-dose group (5 x 10\^7cells)~* High-dose group (1 x 10\^8 cells)
Study: NCT00512252
Drug: Mitoxantrone
Normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00512252
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00512252
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02448069
Drug: Argatroban
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will receive a 3.0 mcg/kg/min continuous infusion of Argatroban, preceded by a 100 mcg/kg bolus. Infusion will be titrated to achieve an aPTT of 2.25 times baseline (not to exceed 10 mcg/kg/min) for a maximum of 12 hours.
Study: NCT01779700
Drug: Fingolimod
Normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 0.5mg each day of 8 week cycle
Study: NCT02966652
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic treatment for patients with primary or secondary male hypogonadism
Study: NCT03451422
Drug: Efavaleukin Alfa
Normalized name: Efavaleukin alfa
DrugBank: Efavaleukin alfa (DB16149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavaleukin Alfa will be administered by subcutaneous (SC) injection in the abdomen, thigh or upper arm.
Study: NCT03387540
Drug: ICI
Normalized name: Ficin
DrugBank: Taraxacum officinale pollen (DB10755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the following list (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32).
Study: NCT01788371
Drug: Telbivudine
Normalized name: Telbivudine
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: About 300 mothers with no treatment observedfrom 28 weeks of pregnancy to the week 4 of postpartun
Study: NCT01788371
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: About 300 mothers treated with lamivudine or telbivudine from 28 weeks of pregancy to the week 4 of postpartum
Study: NCT01115140
Drug: metformin plus placebo
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: metformin 850 mg cp, 2 cps daily
Study: NCT04495140
Drug: [14C]PF-06882961, 50 mg
DrugBank: PF-06882961 (DB16043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of \[14C\]PF-06882961, will be administered as a liquid formulation.
Study: NCT04495140
Drug: PF-06882961, 50 mg and [14C]PF-06882961, 100 ug
DrugBank: PF-06882961 (DB16043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single, oral, unlabeled dose of PF-06882961, 50 mg will be administered as a liquid formulation. Approximately 3 hours after the administration of the unlabeled oral dose, a single dose of \[14C\]PF-06882961 will be administered via intravenous infusion.
Study: NCT01556594
Drug: Nasal Glucagon 1 mg
Normalized name: glucagon Nasal Powder
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01556594
Drug: Nasal Glucagon 2 mg
Normalized name: glucagon Nasal Powder
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01556594
Drug: SC Glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01556594
Drug: Nasal Glucagon 3 mg
Normalized name: glucagon Nasal Powder
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03833440
Drug: Durvalumab (MEDI4736)
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1500 mg, every 4 weeks. CxD1 for each cycle, 1 cycle = 28 days~EXCEPT FOR CYCLE 1 IN ARM C : at C1D8 and cycle 1 = 35 days~c=cycle D= day
Study: NCT03833440
Drug: Monalizumab (IPH2201)
Normalized name: Omalizumab
DrugBank: Monalizumab (DB12824)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1500 mg, every 4 weeks. CXD1 for each cycle, 1 cycle = 28 days~c=cycle D= day
Study: NCT03833440
Drug: Oleclumab (MEDI9447)
Normalized name: Oleclumab
DrugBank: Oleclumab (DB15088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000 mg every 2 week x 4 doses, followed by 3000 mg every 4 weeks. C1D1, C1D15, C2D1, C2D15 and CXD1 for the orther cycles, 1 cycle = 28 days.~c=cycle D= day
Study: NCT03833440
Drug: Ceralasertib (AZD6738)
Normalized name: Ceralasertib
DrugBank: Ceralasertib (DB14917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg bid in Cycle 1, Days 1-7, followed by 7 days on treatment in each cycle between Days 22 and 28.~CxD22-D28 for each cycle, 1 cycle = 28 days EXCEPT FOR CYCLE 1 : at C1D1,C1D29 and cycle 1 = 35 days~c=cycle D= day
Study: NCT03833440
Drug: DOCETAXEL
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2, every 3 weeks. CxD1 for each cycle, 1 cycle = 21 days~c=cycle D= day
Study: NCT03833440
Drug: Savolitinib
Normalized name: savolitinib
DrugBank: Savolitinib (DB12048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg QD~1 cycle = 28 days
Study: NCT01911767
Drug: Dimethyl fumarate
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as specified in treatment arm.
Study: NCT01911767
Drug: Peginterferon beta-1a
Normalized name: Peginterferon Beta-1A
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as specified in treatment arm.
Study: NCT03274076
Drug: Tofacitinib
Normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral medication tofacitinib 5 mg twice a day for 24 weeks.
Study: NCT03879538
Drug: Nitrous Oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A total of three inhalation treatments with 50% Nitrous Oxide plus 50% oxygen (6 total exposure hours) over one week with 2 or 3 days between each session.
Study: NCT03879538
Drug: Oxygen
Normalized name: Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A total of three inhalation treatments with 50% oxygen (6 total exposure hours) over one week with 2 or 3 days between each session.
Study: NCT00651859
Drug: Bimatoprost 0.01% Ophthalmic Solution
Normalized name: Bimatoprost 0.01% Ophthalmic Solution
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bimatoprost 0.01% ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
Study: NCT00651859
Drug: Bimatoprost 0.03% Ophthalmic Solution
Normalized name: Bimatoprost 0.03% Ophthalmic Solution
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bimatoprost 0.03% ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
Study: NCT00651859
Drug: Bimatoprost Vehicle Ophthalmic Solution
Normalized name: bimatoprost Ophthalmic Solution
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bimatoprost vehicle ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
Study: NCT00507494
Drug: pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone 30 mg o.d. tablet for 12 weeks or placebo o.d. tablet for 12 weeks in random order. After 12 wk treatment there is a 4 wk washout out which is followed by switch of study medication in a cross over fashion and a further 12 wk treatment.
Study: NCT02553889
Drug: ISIS 416858
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection
Study: NCT01028287
Drug: ACTH
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with nephrotic range proteinuria randomized to this group will receive 16 units ACTHargel sub-cutaneously every day.
Study: NCT01028287
Drug: ACTH
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with nephrotic range proteinuria randomized to this group will receive 32 units ACTHargel sub-cutaneously every day.
Study: NCT03781375
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered by subcutaneous injection twice a week
Study: NCT04620200
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3mg/kg
Study: NCT04620200
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1mg/kg